Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Roshini Claire Anthony, 19 Sep 2016

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

01 Apr 2016
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Apr 2015
New drug applications approved by US FDA as of 1 – 15 April 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Lower risk of respiratory-related hospitalization after high-dose influenza vaccination in the elderly

Roshini Claire Anthony
01 Aug 2017

Elderly individuals residing in nursing homes had a lower risk of respiratory-related hospital admissions during the influenza season after receiving a high-dose influenza vaccine compared with a standard-dose vaccine, a recent study found.

Eight hundred and twenty three nursing care facilities in the US participated in the study. Individuals aged ≥65 years (mean age 83.6 years, 72 percent female) who had been living in the nursing homes for ≥90 days were randomized to receive either high-dose (60 µg antigen per virus strain; n=26,639) or standard-dose (15 µg antigen per virus strain; n=26,369) influenza vaccine for the 2013–2014 influenza season.

Hospital admission due to respiratory issues was lower among patients who received the high-dose vaccine compared with the standard-dose vaccine (0.185 vs 0.211 per 1,000 resident-days; adjusted relative risk [adjRR], 0.873, 95 percent confidence interval [CI], 0.776–0.982; p=0.023). [Lancet Respir Med 2017;doi:10.1016/S2213-2600(17)30235-7]

Pneumonia- related hospital admissions were also reduced among individuals receiving the high-dose vaccine compared with the standard dose (0.067 vs 0.084 per 1,000 resident-days; adjRR, 0.791, 95 percent CI, 0.267–0.953; p=0.013), as were all-cause admissions (1.021 vs 1.113 per 1,000 resident-days; adjRR, 0.915, 95 percent CI, 0.863–0.970; p=0.0028), while all-cause mortality rate was not affected by vaccine dose (p=0.57).

The reduction in all-cause admission suggests that the impact of the high-dose vaccine extends beyond that of influenza-related respiratory conditions, said the researchers. 

“Establishing improved vaccine effectiveness in a nursing home population is noteworthy, considering this population typically has a reduced vaccine response because of immune senescence and multiple morbidities, and are at a high risk for being admitted to hospital for multiple reasons, in addition to respiratory illness,” said the researchers.

“[S]tandard-dose inactivated influenza vaccines ... are known to be less immunogenic in older adults than in healthier, younger adults,” commented Drs Marc-Alain Widdowson and Joseph Bresee from the US Centers for Disease Control and Prevention, in Nairobi, Kenya, and Atlanta, Georgia, US, respectively. [Lancet Respir Med 2017;doi:10.1016/S2213-2600(17)30290-4]

“[T]his study presents strong evidence that influenza has a major role in seasonal hospital admissions of older nursing home residents ... it seems that high-dose influenza vaccines can reduce this burden substantially better than a standard-dose vaccine,” they said.

However, the researchers cautioned that the main circulating virus strain during the 2013–2014 influenza season was A(H1N1)pdm09, a strain that is considered less virulent than the A/H3N2 strains, and which may have affected the findings, particularly among the elderly population.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Roshini Claire Anthony, 19 Sep 2016

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

01 Apr 2016
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Apr 2015
New drug applications approved by US FDA as of 1 – 15 April 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.